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Stiff person syndrome (SPS) is a rare neurologic disorder characterized by progressively
worsening rigidity and spasms of the axial and limb muscles. Dyspnea has been recently
recognized as a common symptom in SPS,1 and life-threatening respiratory crises have been
occasionally reported and suspected to be responsible for sudden death in these patients.2,3 The
pathophysiologic mechanisms of these respiratory manifestations remain unclear. Some
authors have hypothesized that rigidity and/or spasm of the muscles of the trunk could prevent
normal rib cage movements and excursion of the diaphragm.1
Here, we report the clinical history of a 55-year-old woman affected by SPS since about 10 years,
presenting with crises of severe dyspnea in the past 2 years. The woman also bore several
autoimmune comorbidities illustrated in table.
The clinical onset presented with stiffness of the trunk, with exaggerated lumbar lordosis and
neck hyperextension, causing postural instability and progressively worsening difficulties in
walking until wheelchair dependence. A few months after onset, diffuse painful muscle spasms,
mainly induced by voluntary movements or precipitated by external stimuli, appeared in the
proximal and distal muscles of the 4 limbs. Spasms slowly worsened over time, being re-
sponsible for repeated episodes of muscle and tendon tears. The clinical picture was completed
by progressive urinary retention requiring bladder catheterization, likely due to urethral
sphincter spasm,4 myoclonic jerks of the abdominal and lower limb muscles, mainly triggered
by the attempt to stand up, moderate dysphagia and, finally, acute respiratory crises. The
respiratory crises were triggered by cough, laughter, or activities requiring increased respiratory
efforts, and they were characterized by a sudden onset and severe dyspnea with mild desatu-
ration (SpO2 range of 85%–90%) as assessed by pulse oximetry. Neurologic examination was
remarkable for hyperreflexia in all 4 limbs and positive bilateral Hoffman signs.
MRI examination of the brain and spinal cord was unremarkable. Paraneoplastic profiles were
negative. Laboratory tests revealed positive antibodies against glutamic acid decarboxylase
(4.7 U/mL, >1.0 U/mL positive), a common finding in subjects with SPS. The diagnosis of SPS
was corroborated by electromyographic evidence of continuous motor unit activity in agonist
and antagonist muscles, inconstant 3- to 4-Hz pseudorhythmic myoclonic EMG discharges in
the lower limbs, and long-latency reflexes evoked by innocuous sural nerve stimulation in the
lower limbs.
The patient was unsuccessfully treated with oral prednisone (0.5–1.5 mg/kg/d), several IV
immunoglobulin infusions (400 mg/kg/d ×5 days), and immunosuppressive therapy, initially
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with azathioprine (up to 3 mg/kg/d) and subsequently with
cyclosporine A (up to 4 mg/kg/d). Lately, rituximab (375
mg/m2 IV for 4 doses) was added to the corticosteroid
treatment, which induced a complete depletion of CD20+
B-Cells, but no clinical improvement. Oral diazepam (10–15
mg/d) and baclofen (75 mg/d) were used to control muscle
spasms, with partial benefit. Diazepam doses were not in-
creased beyond 15 mg because of side effects, including
daytime sleepiness and forgetfulness. Over the previous 2
years, respiratory crises occurred with increasing frequency
(up to 2 per week) and severity of dyspnea, thus becoming
a major concern that often required prompt sanitary inter-
ventions and multiple accesses to the emergency department.
In many cases, dyspnea crises could be interrupted only with
IV administration of diazepam. In the attempt to find an
effective alternative therapy for the acute management of re-
spiratory crises, we hospitalized the patients for testing the
efficacy and usability of midazolam (5 mg/1 mL concentra-
tion) via the nasal route.
Midazolam is a short-acting benzodiazepine (BZD), roughly
1.5–2 times more potent than diazepam. When administered
intranasally, midazolam is rapidly absorbed and acts very
quickly, with possible superiority over the IV route when
considering the time needed to place an IV catheter.5,6 In-
tranasal midazolam is both effective and well tolerated in the
acute treatment of status epilepticus. This BDZ has been
approved by the FDA for seizure clusters inMay 2019. Recent
studies have confirmed its safety profile and support the fea-
sibility of intranasal administration as a potential alternative
for the out-of-hospital treatment of seizure emergencies.7
Video 1 shows a representative respiratory crisis observed
during hospitalization. The crisis was almost immediately
interrupted by the nasal administration of midazolam 2.5 mg
(0.5 mL) into each nostril by means of a mucosal atomization
device. Immediately after treatment, the patient experienced
a mild feeling of drowsiness that resolved within 2 hours, but
no other side effects. Systolic and diastolic blood pressure
moderately decreased for a few hours after treatment, but
the values remained within physiologic limits. The average
oxygen saturation levels were maintained within the normal
range.
After we assessed safety and efficacy of treatment in 4 different
occasions in the hospital setting, we trained the patient’s rela-
tives to administer the drug at home. Until now, more than 20
respiratory crises have been effectively and safely treated, with
a frequency of about one administration every 2 weeks.
In conclusion, based on our multiple observations in a single
case, intranasal midazolam administration appears an easily
applicable and rapidly effective alternative treatment for re-
spiratory crises due to spasms of the axial muscles in SPS,
especially when an IV route is not available.
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Table Past or concurrent autoimmune comorbidities experienced by the patient
Autoimmune disease Notes
Idiopathic/immune thrombocytopenic
purpura
Onset in childhood, with spontaneous remission.
Antiphospholipid syndrome with high
anticardiolipin IgG (ACA) titres
Concurrent disease responsible for recurrent venous thrombosis episodes in the lower limbs, treated
with warfarin.
Undifferentiated connective tissue disease Concurrent disease. Positive antinuclear antigen, ANA (1:160). Capillaroscopy showing microvascular
abnormalities.
Myasthenia gravis Diagnosed about 20 years ago based on clinical symptoms (muscle weakness with fatigue, fluctuating
diplopia, and ptosis), presence of antiacetylcholine receptor (AChR) antibody and electrophysiologic
abnormalities (single fiber EMG). At present considered in remission based on clinical symptoms,
negative AChR antibody testing, and normal electrophysiologic assessment (single fiber EMG and
repetitive nerve stimulation) on 2 different occasions. Multiple chest CT scans were negative for thymic
abnormalities.
Insulin-dependent diabetes mellitus Concurrent disease.
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